138 related articles for article (PubMed ID: 17099560)
21. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.
Elkader AK; Brands B; Dunn E; Selby P; Sproule BA
J Clin Psychopharmacol; 2009 Feb; 29(1):77-81. PubMed ID: 19142113
[TBL] [Abstract][Full Text] [Related]
22. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
Eap CB; Bertschy G; Powell K; Baumann P
J Clin Psychopharmacol; 1997 Apr; 17(2):113-7. PubMed ID: 10950475
[TBL] [Abstract][Full Text] [Related]
23. Methadone and antiretroviral medications, part I.
Gourevitch MN; Friedland GH
AIDS Clin Care; 1999 Apr; 11(4):30-1 contd. PubMed ID: 11366210
[TBL] [Abstract][Full Text] [Related]
24. Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
Garrido MJ; Trocóniz IF
J Pharmacol Toxicol Methods; 1999 Oct; 42(2):61-6. PubMed ID: 10924887
[TBL] [Abstract][Full Text] [Related]
25. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
[TBL] [Abstract][Full Text] [Related]
26. Contemporary methods in pharmacotherapy in the opiate dependent treatment.
Radomska M; Bisaga A; Popik P
Przegl Lek; 2000; 57(10):509-18. PubMed ID: 11199877
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.
Boulton DW; Arnaud P; DeVane CL
Clin Pharmacol Ther; 2001 Jul; 70(1):48-57. PubMed ID: 11452244
[TBL] [Abstract][Full Text] [Related]
28. Fluctuations in (R,S)-methadone pharmacokinetics and response among long-term methadone maintenance patients.
Mitchell TB; Dyer KR; Newcombe D; Somogyi AA; White JM
Addict Biol; 2006 Jun; 11(2):170-4. PubMed ID: 16800831
[TBL] [Abstract][Full Text] [Related]
29. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Smith PF; Kearney BP; Liaw S; Cloen D; Bullock JM; Haas CE; Yale K; Booker BM; Berenson CS; Coakley DF; Flaherty JF
Pharmacotherapy; 2004 Aug; 24(8):970-7. PubMed ID: 15338845
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.
Kharasch ED; Bedynek PS; Park S; Whittington D; Walker A; Hoffer C
Clin Pharmacol Ther; 2008 Oct; 84(4):497-505. PubMed ID: 19238655
[TBL] [Abstract][Full Text] [Related]
31. Long-acting opioid-agonists in the treatment of heroin addiction: why should we call them "substitution"?
Gerra G; Maremmani I; Capovani B; Somaini L; Berterame S; Tomas-Rossello J; Saenz E; Busse A; Kleber H
Subst Use Misuse; 2009; 44(5):663-71. PubMed ID: 19360539
[TBL] [Abstract][Full Text] [Related]
32. L-Methadone and D,L-methadone in methadone maintenance treatment: a comparison of therapeutic effectiveness and plasma concentrations.
de Vos JW; Ufkes JG; Kaplan CD; Tursch M; Krause JK; van Wilgenburg H; Woodcock BG; Staib AH
Eur Addict Res; 1998 Sep; 4(3):134-41. PubMed ID: 9742275
[TBL] [Abstract][Full Text] [Related]
33. Heroin anticraving medications: a systematic review.
Fareed A; Vayalapalli S; Casarella J; Amar R; Drexler K
Am J Drug Alcohol Abuse; 2010 Nov; 36(6):332-41. PubMed ID: 20955107
[TBL] [Abstract][Full Text] [Related]
34. Cytochrome P450 2D6 genotype and methadone steady-state concentrations.
Eap CB; Broly F; Mino A; Hämmig R; Déglon JJ; Uehlinger C; Meili D; Chevalley AF; Bertschy G; Zullino D; Kosel M; Preisig M; Baumann P
J Clin Psychopharmacol; 2001 Apr; 21(2):229-34. PubMed ID: 11270921
[TBL] [Abstract][Full Text] [Related]
35. Interindividual variability of methadone response: impact of genetic polymorphism.
Li Y; Kantelip JP; Gerritsen-van Schieveen P; Davani S
Mol Diagn Ther; 2008; 12(2):109-24. PubMed ID: 18422375
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
37. Opioid Treatment for Neonatal Opioid Withdrawal Syndrome: Current Challenges and Future Approaches.
McPhail BT; Emoto C; Butler D; Fukuda T; Akinbi H; Vinks AA
J Clin Pharmacol; 2021 Jul; 61(7):857-870. PubMed ID: 33382111
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment.
Maas J; Barton G; Maskrey V; Pinto H; Holland R
Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419
[TBL] [Abstract][Full Text] [Related]
39. A therapeutic use of the methadone fluvoxamine drug interaction.
DeMaria PA; Serota RD
J Addict Dis; 1999; 18(4):5-12. PubMed ID: 10631960
[TBL] [Abstract][Full Text] [Related]
40. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401.
Gerber JG; Rosenkranz S; Segal Y; Aberg J; D'Amico R; Mildvan D; Gulick R; Hughes V; Flexner C; Aweeka F; Hsu A; Gal J;
J Acquir Immune Defic Syndr; 2001 Jun; 27(2):153-60. PubMed ID: 11404537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
